Sustained Reduction in Tumour Size Seen In Pancreatic Trial
Released
Released
Announcement PDF
ABN 16 165 160 841
ASX RELEASE
25 July 2024
SUSTAINED REDUCTION IN TUMOUR SIZE SEEN IN PATIENTS IN PANCREATIC CANCER TRIAL
HIGHLIGHTS
•
50% of the required patient responses in the initial enrolment stage of the Company’s Phase
2a ACCENT trial have now been confirmed
•
The ACCENT trial explores the activity of narmafotinib, in combination with standard-of-care
chemotherapy, in advanced pancreatic cancer patients
•
The ACCENT trial protocol requires that at least six (6) of the first 26 patients enrolled achieve
this level of response
•
A further three confirmed partial responses are required to initiate the complete enrolment of
the trial
Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is
pleased to announce that three (3) patients enrolled in the Company’s Phase 2a clinical trial
investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) have
recorded a confirmed partial response. The formal term ‘confirmed partial response’ means there is
at least a 30% decrease in the overall size of tumour lesions, and no new tumour lesions, in these
patients sustained over a two month period.
Of the six (6) patients currently assessed at the four month time point, in addition to the three (3)
confirmed partial responses, two (2) additional patients have recorded sustained stable disease.
Amplia CEO and MD Dr Chris Burns commented: “To be reporting that three confirmed partial
responses have been observed so early in this stage of the trial is extremely encouraging. We are well
on track to reach the efficacy threshold of six confirmed partial or complete responses by the end of
this quarter, which will then allow us to restart the trial to recruit the full cohort of fifty patients.”
The Company recently announced completion of enrolment of the first 26 patients in the trial as part
of the industry-standard Simon’s Two-Stage Trial design. Once six (6) confirmed partial or complete
responses are obtained then an additional 24 patients will be enrolled, giving a total of 50 patients for
the trial.
The Company will provide further updates on the trial as recruitment proceeds.
This ASX announcement was approved and authorised for release by the Board of Amplia
Therapeutics.
Level 17, 350 Queen Street, Melbourne VIC 3000
Email info@ampliatx.com
www.ampliatx.com
About Narmafotinib
Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein overexpressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in
solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising
data in a range of preclinical cancer studies. The drug has successfully completed a healthy volunteer
study, and is currently in an open-label Phase 2a trial in pancreatic cancer where a combination of
narmafotinib and the chemotherapies gemcitabine and Abraxane® is being assessed for safety,
tolerability and efficacy.
About the ACCENT Trial
The ACCENT trial is entitled ‘A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics,
Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic
Cancer Patients’.
The ACCENT trial explores the use of narmafotinib in combination with standard-of-care
chemotherapy of gemcitabine and Abraxane® in first-line patients with advanced pancreatic cancer.
The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed
in November 2023, identified a 400 mg oral daily dose of narmafotinib, given in the days preceding
regular chemotherapy infusion, as safe and well tolerated.
This second stage (Phase 2a) of the trial is designed to assess drug efficacy in combination with
gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration
on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival
(OS). Safety and tolerability will continue to be assessed.
More information about the ACCENT trial, including a list of participating sites, can be found via the
Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298.
Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com
About Amplia Therapeutics Limited
Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal
Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the
field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic
and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic
pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter
(@ampliatx), Threads (@ampliatx) and LinkedIn.
Share your feedback
Discover